- Home
- IAG vs RNA Comparison
IAG vs RNA Comparison
Compare IAG & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IAG | RNA |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 227.6M |
| IPO Year | 2002 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IAG | RNA |
|---|---|---|
| Price | $18.40 | $13.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $17.75 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 6.8M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.84 | $88.12 |
| Revenue Next Year | $1.33 | $18.11 |
| P/E Ratio | $18.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $13.06 |
| 52 Week High | $24.87 | $73.06 |
Technical Indicators
Market Signals| Indicator | IAG | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 5.72 |
| Support Level | $17.65 | $13.06 |
| Resistance Level | $22.47 | $72.52 |
| Average True Range (ATR) | 1.01 | 1.00 |
| MACD | -0.58 | -0.21 |
| Stochastic Oscillator | 1.52 | 16.44 |
Price Performance
Historical ComparisonAbout IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.